AUDENTES THERAPEUTICS Overview
Company Headquarters: San Francisco, US
Founded: 2013
Workforce: ~500
Company Working: Audentes Therapeutics (Audentes) is a clinical-stage biotechnology company. The company is involved in developing adeno-associated virus-based (AAV) genetic medicines. Audentes is developing AT132, used for the treatment of X-linked myotubular myopathy; AT845, for the treatment of Pompe disease; AT342 to treat Crigler-Najjar syndrome; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CPVT), and is involved developing vector-based antisense treatments for the treatment of myotonic dystrophy.
Strategy
Audentes focused on commercializing and developing gene therapy products for patients living with rare life-threatening diseases such as Pompe disease, X-linked myotubular myopathy, Duchenne muscular dystrophy, and many more. The company has collaborated with Genethon for research & development, manufacture, and commercialization of products used for the treatment of such diseases.
